Barclays PLC Has $1.96 Million Stock Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Barclays PLC raised its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 410.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 245,045 shares of the company's stock after buying an additional 197,033 shares during the quarter. Barclays PLC owned about 0.36% of EyePoint Pharmaceuticals worth $1,959,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Bank of New York Mellon Corp raised its position in shares of EyePoint Pharmaceuticals by 32.6% during the second quarter. Bank of New York Mellon Corp now owns 204,892 shares of the company's stock valued at $1,783,000 after buying an additional 50,388 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of EyePoint Pharmaceuticals by 271.0% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,888 shares of the company's stock worth $95,000 after acquiring an additional 7,953 shares during the period. Panagora Asset Management Inc. grew its holdings in shares of EyePoint Pharmaceuticals by 205.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 120,721 shares of the company's stock worth $1,050,000 after purchasing an additional 81,201 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of EyePoint Pharmaceuticals by 32.6% during the 2nd quarter. Rhumbline Advisers now owns 76,833 shares of the company's stock worth $668,000 after purchasing an additional 18,897 shares in the last quarter. Finally, Fiera Capital Corp increased its position in shares of EyePoint Pharmaceuticals by 0.9% during the second quarter. Fiera Capital Corp now owns 677,038 shares of the company's stock valued at $5,890,000 after purchasing an additional 5,920 shares during the period. 99.41% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on EYPT. StockNews.com raised EyePoint Pharmaceuticals to a "sell" rating in a research report on Saturday, September 21st. Robert W. Baird reduced their price objective on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating for the company in a report on Monday, November 11th. Chardan Capital upped their target price on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the company a "buy" rating in a research note on Friday, November 8th. Scotiabank assumed coverage on shares of EyePoint Pharmaceuticals in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $18.00 price target for the company. Finally, HC Wainwright reiterated a "buy" rating and issued a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $25.71.

EyePoint Pharmaceuticals Stock Performance

Shares of NASDAQ EYPT traded down $0.38 during mid-day trading on Friday, hitting $7.20. 673,675 shares of the stock were exchanged, compared to its average volume of 941,143. EyePoint Pharmaceuticals, Inc. has a twelve month low of $6.90 and a twelve month high of $30.99. The stock's fifty day simple moving average is $9.36 and its two-hundred day simple moving average is $9.03. The company has a market cap of $491.41 million, a P/E ratio of -3.60 and a beta of 1.45.

EyePoint Pharmaceuticals Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.